Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 29, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Fused Imidazole Derivative, Preparation Method Therefor, And Medical Use ThereofSHANGHAI HENGRUI PHARMACEUTICALOct 28, 2026JAMES POOLE
Mucosal-Associated Invariant T (Mait) Cells Expressing Chimeric Antigen ReceptorsASSISTANCE PUBLIQUE HPITAUX DE PARIS APHPOct 28, 2026GOODWIN PROCTER UK
Thrb Receptor Agonist Compound And Preparation Method And Use ThereofTERNSOct 26, 2026AWA DENMARK
Ripretinib For Treating Gastrointestinal Stromal TumorsDECIPHERA PHARMACEUTICALSOct 22, 2026ALFRED E TIEFENBACHER
Methods Using Administration Of Medium Chain Triglycerides (Mct) Prior To A Meal To Increase Ketone Production From The MctsNESTLEOct 16, 2026ABBOTT LABORATORIES
Composition For Reducing Hepatic Triglycerides And/Or Improving Glucose MetabolismUNIVERSIT LAVALOct 12, 2026FRESENIUS KABI DEUTSCHLAND
Binding Molecules For Bcma And Cd3AMGEN RESEARCH MUNICHOct 6, 2026STRAWMAN
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 30, 2026MAIWALD PATENTANWALTS
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 30, 2026KERNEBECK PATENTANWALTS
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHASep 29, 2026STRAWMAN

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 29, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS24
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 26, 2025Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIM19
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECA14
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Nov 2, 2016Multiple-Variable Dose Regimen For Treating Tnfalpha-Related DisordersABBVIE BIOTECHNOLOGY11